Assessment of non-myelotoxic agents as a preparatory regimen for hematopoietic stem cell gene therapy
- 26 October 2024
- journal article
- research article
- Published by Springer Nature in Human Cell
- Vol. 38 (1) , 1-12
Abstract
RAG2 deficiency is characterized by a lack of B and T lymphocytes, causing severe lethal infections. Currently, RAG2 deficiency is treated with a Hematopoietic Stem Cell transplantation (HSCT). Most conditioning regimens used before HSCT consist of alkylating myelotoxic agents with or without irradiation and affect growth and development of pediatric patients. Here, we developed a non-myelotoxic regimen using G-CSF, VLA-4I or AMD3100. These agents are known HSC mobilizers or affect bone marrow (BM) permeability and may support the homing of HSCs to the BM, without inducing major side effects. Female Rag2−/− mice were pre-treated with Busulfan (BU), G-CSF, VLA-4I or AMD3100 and transplanted with male BM cells transduced with a lentiviral vector carrying codon optimized human RAG2 (RAG2co). Peripheral blood cell counts increased significantly after G-CSF, VLA-4I and AMD3100 treatment, but not after BU. Reconstitution of PB lymphocytes was comparable for all groups with full immune reconstitution at 6 months post transplantation, despite different methods of conditioning. Survival of mice pre-treated with non-myelotoxic agents was significantly higher than after BU treatment. Here, we show that the non-myelotoxic agents G-CSF, VLA-4I, and AMD3100 are highly effective as conditioning regimen before HSC gene therapy and can be used as an alternative to BU.Keywords
Funding Information
- Scientific and Technological Research Council of Turkey (1002-220S338, 2221-2017/2)
- Hacettepe Üniversitesi (TUK-2019-17760, TAY2022-20436)
- European Union Framework Program 7 (HEALTH-2010-261387)
This publication has 56 references indexed in Scilit:
- Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cellsCell, 2022
- Conditioning Regimens for Hematopoietic Cell Transplantation in Primary ImmunodeficiencyCurrent Allergy and Asthma Reports, 2019
- Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood cancer and cancer in the reproductive ageCochrane Database of Systematic Reviews, 2019
- Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern EraJAMA Oncology, 2019
- New agents in HSC mobilizationInternational Journal of Hematology, 2016
- Molecular Mechanism of V(D)J Recombination from Synaptic RAG1-RAG2 Complex StructuresCell, 2015
- Lentiviral Gene Transduction of Mouse and Human Hematopoietic Stem Cells2014
- Educational paperEuropean Journal of Pediatrics, 2011
- More than just SCID—The phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2Clinical Immunology, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009